Sood S L, Balaraman V, Finn K C, Wilkerson S Y, Mundie T G, Easa D
Department of Pediatrics, Kapiolani Medical Center for Women and Children, John A. Burns School of Medicine, Honolulu, HI 96826, USA.
Pediatr Pulmonol. 1996 Dec;22(6):376-86. doi: 10.1002/(SICI)1099-0496(199612)22:6<376::AID-PPUL6>3.0.CO;2-H.
Abnormalities of pulmonary surfactant function have been described in association with the acute respiratory distress syndrome (ARDS). Because gram-negative sepsis is a common cause of ARDS, we treated neonatal piglets with Escherichia coli endotoxin to create a neonatal ARDS model. We hypothesized that under these conditions administration of exogenous surfactant would improve pulmonary function. Study groups included: control (n-8), Exosurf (5 mL/kg, 13.5 mg phospholipid/mL, n-7), Survanta (4 mL/kg, 25 mg phospholipid/mL, n-6), and saline (5 mL/kg, n = 6). E. coli endotoxin 12 micrograms/kg was infused over 30 min and resulted in significant pulmonary and hemodynamic abnormalities, histopathologic evidence of nonhomogeneous lung injury, and elevated protein levels in bronchoalveolar lavage washings. Neither Exosurf nor Survanta ameliorated the pulmonary effects of endotoxin. Instead, there was a prolonged decrease in arterial oxygen tension (PaO2) and dynamic lung compliance after administration of surfactant and saline. Distribution of a bolus of Exosurf was uneven throughout the lung. We conclude that in this neonatal piglet model of ARDS, bolus surfactant administration had a detrimental effect on oxygenation and pulmonary function.
肺表面活性物质功能异常已被描述为与急性呼吸窘迫综合征(ARDS)相关。由于革兰氏阴性菌败血症是ARDS的常见病因,我们用大肠杆菌内毒素治疗新生仔猪以建立新生动物ARDS模型。我们假设在这些条件下给予外源性表面活性物质会改善肺功能。研究组包括:对照组(n = 8)、Exosurf组(5 mL/kg,13.5 mg磷脂/mL,n = 7)、Survanta组(4 mL/kg,25 mg磷脂/mL,n = 6)和生理盐水组(5 mL/kg,n = 6)。将12微克/千克的大肠杆菌内毒素在30分钟内输注完毕,结果导致明显的肺和血流动力学异常、肺损伤不均匀的组织病理学证据以及支气管肺泡灌洗洗液中蛋白质水平升高。Exosurf和Survanta均未改善内毒素对肺的影响。相反,给予表面活性物质和生理盐水后,动脉血氧分压(PaO2)和动态肺顺应性出现了持续下降。一次大剂量Exosurf在肺内的分布不均匀。我们得出结论,在这个新生仔猪ARDS模型中,一次性给予表面活性物质对氧合和肺功能有不利影响。